CN1196702C - 二环聚氨基酸金属配合物、它们的制备方法及在医疗图像中的用途 - Google Patents

二环聚氨基酸金属配合物、它们的制备方法及在医疗图像中的用途 Download PDF

Info

Publication number: CN1196702C
Authority: CN; China
Prior art keywords: formula; compound; chelate; metallo; group
Prior art date: 1999-06-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CNB008086060A

Other languages

English (en)

Chinese (zh)

Other versions

CN1354751A (zh

Inventor

M·波特

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Guerbet SA

Original Assignee

Guerbet SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-09

Filing date

2000-06-08

Publication date

2005-04-13

2000-06-08 Application filed by Guerbet SA filed Critical Guerbet SA

2002-06-19 Publication of CN1354751A publication Critical patent/CN1354751A/zh

2005-04-13 Application granted granted Critical

2005-04-13 Publication of CN1196702C publication Critical patent/CN1196702C/zh

2020-06-08 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 11
229910052751 metal Inorganic materials 0.000 title claims description 7
239000002184 metal Substances 0.000 title claims description 7
238000002059 diagnostic imaging Methods 0.000 title abstract description 3
125000002619 bicyclic group Chemical group 0.000 title 1
229920001308 poly(aminoacid) Polymers 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 89
239000000203 mixture Substances 0.000 claims description 49
239000002585 base Substances 0.000 claims description 34
238000006243 chemical reaction Methods 0.000 claims description 30
239000013522 chelant Substances 0.000 claims description 27
239000002253 acid Substances 0.000 claims description 26
229910052794 bromium Inorganic materials 0.000 claims description 20
229910052740 iodine Inorganic materials 0.000 claims description 17
150000001412 amines Chemical class 0.000 claims description 12
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 11
229910052801 chlorine Inorganic materials 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
230000005298 paramagnetic effect Effects 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
229910052688 Gadolinium Inorganic materials 0.000 claims description 4
125000003368 amide group Chemical group 0.000 claims description 4
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 4
230000007062 hydrolysis Effects 0.000 claims description 4
238000006460 hydrolysis reaction Methods 0.000 claims description 4
239000000654 additive Substances 0.000 claims description 3
230000000996 additive effect Effects 0.000 claims description 3
239000003513 alkali Substances 0.000 claims description 3
229910002091 carbon monoxide Inorganic materials 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
239000003153 chemical reaction reagent Substances 0.000 claims description 3
229910021645 metal ion Inorganic materials 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 2
150000001447 alkali salts Chemical class 0.000 claims description 2
238000009472 formulation Methods 0.000 claims description 2
125000000524 functional group Chemical group 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
125000004185 ester group Chemical group 0.000 claims 1
150000001408 amides Chemical class 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
239000000243 solution Substances 0.000 description 33
239000007864 aqueous solution Substances 0.000 description 28
238000001556 precipitation Methods 0.000 description 28
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
238000004128 high performance liquid chromatography Methods 0.000 description 26
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
229910052757 nitrogen Inorganic materials 0.000 description 18
239000000047 product Substances 0.000 description 17
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
238000003756 stirring Methods 0.000 description 15
238000002360 preparation method Methods 0.000 description 14
239000011347 resin Substances 0.000 description 14
229920005989 resin Polymers 0.000 description 14
-1 Gd 3+ Chemical class 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
150000002500 ions Chemical class 0.000 description 11
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
150000001414 amino alcohols Chemical class 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000000460 chlorine Substances 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
239000002244 precipitate Substances 0.000 description 7
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
238000000926 separation method Methods 0.000 description 6
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 6
239000007787 solid Substances 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 5
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 5
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 5
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
150000001768 cations Chemical class 0.000 description 5
239000002872 contrast media Substances 0.000 description 5
238000001035 drying Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
229920001429 chelating resin Polymers 0.000 description 4
239000007795 chemical reaction product Substances 0.000 description 4
238000006698 hydrazinolysis reaction Methods 0.000 description 4
239000003456 ion exchange resin Substances 0.000 description 4
229920003303 ion-exchange polymer Polymers 0.000 description 4
230000005291 magnetic effect Effects 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 3
XRSQZFJLEPBPOZ-UHFFFAOYSA-N 4-amino-2-methylbenzoic acid Chemical compound CC1=CC(N)=CC=C1C(O)=O XRSQZFJLEPBPOZ-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
102100021935 C-C motif chemokine 26 Human genes 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
FDQSRULYDNDXQB-UHFFFAOYSA-N benzene-1,3-dicarbonyl chloride Chemical compound ClC(=O)C1=CC=CC(C(Cl)=O)=C1 FDQSRULYDNDXQB-UHFFFAOYSA-N 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
238000011097 chromatography purification Methods 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002118 epoxides Chemical class 0.000 description 3
229960000890 hydrocortisone Drugs 0.000 description 3
238000005984 hydrogenation reaction Methods 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
150000002466 imines Chemical class 0.000 description 3
238000004237 preparative chromatography Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
KULQACNMKIDJNN-GASJEMHNSA-N (2r,3s,4r,5r)-1-aminohexane-1,2,3,4,5,6-hexol Chemical compound NC(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO KULQACNMKIDJNN-GASJEMHNSA-N 0.000 description 2
FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 2
KSILMCDYDAKOJD-UHFFFAOYSA-N 2-aminoisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(N)C(=O)C2=C1 KSILMCDYDAKOJD-UHFFFAOYSA-N 0.000 description 2
VACJHIUSZPBOOF-UHFFFAOYSA-N 3-aminopropane-1,1-diol Chemical compound NCCC(O)O VACJHIUSZPBOOF-UHFFFAOYSA-N 0.000 description 2
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000013019 agitation Methods 0.000 description 2
AJXBTRZGLDTSST-UHFFFAOYSA-N amino 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)ON AJXBTRZGLDTSST-UHFFFAOYSA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
150000001555 benzenes Chemical class 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
239000011575 calcium Substances 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
238000004891 communication Methods 0.000 description 2
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
150000007520 diprotic acids Chemical class 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
150000003949 imides Chemical class 0.000 description 2
239000011630 iodine Substances 0.000 description 2
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
238000009206 nuclear medicine Methods 0.000 description 2
108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000005408 paramagnetism Effects 0.000 description 2
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
239000000088 plastic resin Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
229960002920 sorbitol Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
WQINSVOOIJDOLJ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetic acid Chemical compound C1=CC=C2C(=O)N(CC(=O)O)C(=O)C2=C1 WQINSVOOIJDOLJ-UHFFFAOYSA-N 0.000 description 1
GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 1
ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
235000014653 Carica parviflora Nutrition 0.000 description 1
241000243321 Cnidaria Species 0.000 description 1
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000511739 Melampyrum Species 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
229940059260 amidate Drugs 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
229910000071 diazene Inorganic materials 0.000 description 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000000428 dust Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229910001411 inorganic cation Inorganic materials 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002531 isophthalic acids Chemical class 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
229910000474 mercury oxide Inorganic materials 0.000 description 1
UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000005897 peptide coupling reaction Methods 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
150000004965 peroxy acids Chemical class 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000005544 phthalimido group Chemical group 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920006393 polyether sulfone Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000007348 radical reaction Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
238000002602 scintillography Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
229960001866 silicon dioxide Drugs 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000006478 transmetalation reaction Methods 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000006886 vinylation reaction Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polyamides (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

CNB008086060A 1999-06-09 2000-06-08 二环聚氨基酸金属配合物、它们的制备方法及在医疗图像中的用途 Expired - Fee Related CN1196702C (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9907283A FR2794744B1 (fr)	1999-06-09	1999-06-09	Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
FR99/07283		1999-06-09

Publications (2)

Publication Number	Publication Date
CN1354751A CN1354751A (zh)	2002-06-19
CN1196702C true CN1196702C (zh)	2005-04-13

Family

ID=9546571

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CNB008086060A Expired - Fee Related CN1196702C (zh)	1999-06-09	2000-06-08	二环聚氨基酸金属配合物、它们的制备方法及在医疗图像中的用途

Country Status (22)

Country	Link
US (1)	US6440956B1 (de)
EP (1)	EP1183255B1 (de)
JP (1)	JP4719391B2 (de)
KR (1)	KR20020008218A (de)
CN (1)	CN1196702C (de)
AT (1)	ATE233762T1 (de)
AU (1)	AU5540400A (de)
BR (1)	BR0011436A (de)
CA (1)	CA2376497C (de)
DE (1)	DE60001564T2 (de)
DK (1)	DK1183255T3 (de)
ES (1)	ES2188556T3 (de)
FR (1)	FR2794744B1 (de)
HU (1)	HU227966B1 (de)
IL (2)	IL146304A0 (de)
MX (1)	MXPA01011439A (de)
NO (1)	NO321121B1 (de)
PL (1)	PL216974B1 (de)
PT (1)	PT1183255E (de)
RU (1)	RU2232763C2 (de)
TR (1)	TR200103525T2 (de)
WO (1)	WO2000075141A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20011706A1 (it) *	2001-08-03	2003-02-03	Bracco Imaging Spa	Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic
US8518373B2 (en)	2001-08-03	2013-08-27	Bracco Imaging Spa	Ionic and non-ionic radiographic contrast agents for use in combined X-ray and nuclear magnetic resonance diagnostics
FR2836916B1 (fr) *	2002-03-05	2004-06-11	Guerbet Sa	Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
DE10307759B3 (de) *	2003-02-19	2004-11-18	Schering Ag	Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
JP2004307356A (ja) *	2003-04-02	2004-11-04	Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai	新規なデンドリマーおよび造影剤
FR2856689A1 (fr) *	2003-06-25	2004-12-31	Guerbet Sa	Composes specifiques a forte relaxivite
FR2857967B1 (fr) *	2003-07-25	2015-04-24	Centre Nat Rech Scient	Complexes de lanthanide, leur preparation et leurs utilisations
FR2867473B1 (fr) *	2004-03-12	2006-06-23	Guerbet Sa	Compose de porphyrines et utilisation a haut champ en irm
CN1993357B (zh)	2004-07-02	2011-10-19	伯拉考成像股份公司	用于磁共振成像(mri)的含有具有多羟基化取代基的螯合部分的高弛豫造影剂
FR2875410B1 (fr) *	2004-09-23	2012-11-16	Guerbet Sa	Composes de diagnostique pour le ciblage de recpteur a chimiokines
CN100355806C (zh) *	2005-03-04	2007-12-19	华东师范大学	端氨基嵌段聚氧乙烯改性的钆配合物及其合成方法
FR2883562B1 (fr) *	2005-03-24	2009-02-27	Guerbet Sa	Chelates lipophiles et leur utilisation en imagerie
US8986650B2 (en)	2005-10-07	2015-03-24	Guerbet	Complex folate-NOTA-Ga68
JP5368099B2 (ja) *	2005-10-07	2013-12-18	ゲルベ	ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
FR2891830B1 (fr) *	2005-10-07	2011-06-24	Guerbet Sa	Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR2914304B1 (fr) *	2007-03-28	2012-11-16	Guerbet Sa	Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) *	2007-03-28	2008-10-03	Guerbet Sa	Composes pour le diagnostic de l'apoptose.
DE102007058220A1 (de)	2007-12-03	2009-06-04	Bayer Schering Pharma Aktiengesellschaft	Dimere macrocyclisch substituierte Benzolderivate
FR2942227B1 (fr)	2009-02-13	2011-04-15	Guerbet Sa	Utilisation de tampons pour la complexation de radionucleides
IN2012DN02586A (de) *	2009-09-28	2015-08-28	Univ Kentucky Res Found
CA2909919C (fr)	2013-04-26	2022-07-12	Guerbet	Formulation de produit de contraste et son procede de preparation associe
GB201610738D0 (en) *	2016-06-20	2016-08-03	Ge Healthcare As	Chelate compounds
CA3044877A1 (en)	2016-11-28	2018-05-31	Bayer Pharma Aktiengesellschaft	High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
ES2813077T3 (es) *	2016-12-21	2021-03-22	Ge Healthcare As	Compuestos quelatos de manganeso basados en macrociclo de tetraazabiciclo adecuados como agentes de imagen de IRM
EP3728168B1 (de) *	2017-12-20	2022-03-30	General Electric Company	Anionische chelatverbindungen
ES2841070T3 (es)	2018-08-06	2021-07-07	Bracco Imaging Spa	Agentes de contraste basados en PCTA que comprenden gadolinio
JP7520007B2 (ja)	2018-11-23	2024-07-22	バイエルアクチェンゲゼルシャフト	造影剤の製剤およびその調製方法
FR3091873B1 (fr)	2019-01-17	2020-12-25	Guerbet Sa	Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
US11370804B2 (en)	2019-01-17	2022-06-28	Guerbet	Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
US11426470B2 (en)	2019-01-17	2022-08-30	Guerbet	Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
FR3091872B1 (fr) *	2019-01-17	2020-12-25	Guerbet Sa	Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
FI4143153T3 (fi) *	2020-07-16	2023-12-20	Guerbet Sa	Menetelmä 2-bromiglutaarihapon diesterien synteesiä varten
CN115722276B (zh) *	2022-11-15	2024-06-18	江苏美亚科泽过滤技术有限公司	一种粒状多效吸附剂组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4001655A1 (de) *	1990-01-18	1991-07-25	Schering Ag	6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE3825040A1 (de) *	1988-07-20	1990-01-25	Schering Ag, 13353 Berlin	5- oder 6-ring- enthaltende makrocyclische polyaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
FR2644785B1 (fr) *	1989-03-24	1991-07-05	Guerbet Sa	Nouveaux ligands macrocycliques azotes, procede de preparation, complexes metalliques formes par ces ligands et composition de diagnostic les contenant
US5554748A (en) *	1989-04-07	1996-09-10	Nycomed Salutar, Inc.	Adducts of macrocyclic chelants
HUT67602A (en) *	1991-12-10	1995-04-28	Dow Chemical Co	Process for producing bicyclo-polyaza-macrocyclo-carboxylic acid complexes, their conjugates and contrast materials containing them
FR2736051B3 (fr) *	1995-06-29	1997-09-26	Guerbet Sa	Complexes metalliques de polyaminoacides, leur procede de preparation et leur utilisation en imagerie diagnostique

1999
- 1999-06-09 FR FR9907283A patent/FR2794744B1/fr not_active Expired - Fee Related
2000
- 2000-06-08 HU HU0201468A patent/HU227966B1/hu not_active IP Right Cessation
- 2000-06-08 KR KR1020017015705A patent/KR20020008218A/ko not_active Application Discontinuation
- 2000-06-08 DK DK00940473T patent/DK1183255T3/da active
- 2000-06-08 IL IL14630400A patent/IL146304A0/xx active IP Right Grant
- 2000-06-08 JP JP2001502423A patent/JP4719391B2/ja not_active Expired - Lifetime
- 2000-06-08 ES ES00940473T patent/ES2188556T3/es not_active Expired - Lifetime
- 2000-06-08 PT PT00940473T patent/PT1183255E/pt unknown
- 2000-06-08 MX MXPA01011439A patent/MXPA01011439A/es active IP Right Grant
- 2000-06-08 TR TR2001/03525T patent/TR200103525T2/xx unknown
- 2000-06-08 EP EP00940473A patent/EP1183255B1/de not_active Expired - Lifetime
- 2000-06-08 AT AT00940473T patent/ATE233762T1/de active
- 2000-06-08 PL PL352483A patent/PL216974B1/pl unknown
- 2000-06-08 CN CNB008086060A patent/CN1196702C/zh not_active Expired - Fee Related
- 2000-06-08 CA CA002376497A patent/CA2376497C/fr not_active Expired - Fee Related
- 2000-06-08 AU AU55404/00A patent/AU5540400A/en not_active Abandoned
- 2000-06-08 US US09/589,345 patent/US6440956B1/en not_active Expired - Lifetime
- 2000-06-08 DE DE60001564T patent/DE60001564T2/de not_active Expired - Lifetime
- 2000-06-08 BR BR0011436-7A patent/BR0011436A/pt not_active Application Discontinuation
- 2000-06-08 RU RU2002100125/04A patent/RU2232763C2/ru not_active IP Right Cessation
- 2000-06-08 WO PCT/FR2000/001591 patent/WO2000075141A1/fr not_active Application Discontinuation
2001
- 2001-11-01 IL IL146304A patent/IL146304A/en not_active IP Right Cessation
- 2001-12-07 NO NO20015991A patent/NO321121B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
FR2794744A1 (fr)	2000-12-15
CA2376497C (fr)	2009-10-20
FR2794744B1 (fr)	2001-09-21
HUP0201468A3 (en)	2010-01-28
US6440956B1 (en)	2002-08-27
MXPA01011439A (es)	2002-06-04
NO321121B1 (no)	2006-03-20
IL146304A0 (en)	2002-07-25
CA2376497A1 (fr)	2000-12-14
CN1354751A (zh)	2002-06-19
JP2003501430A (ja)	2003-01-14
WO2000075141A1 (fr)	2000-12-14
EP1183255B1 (de)	2003-03-05
NO20015991D0 (no)	2001-12-07
JP4719391B2 (ja)	2011-07-06
NO20015991L (no)	2002-02-06
PL216974B1 (pl)	2014-05-30
RU2232763C2 (ru)	2004-07-20
DK1183255T3 (da)	2003-06-02
AU5540400A (en)	2000-12-28
TR200103525T2 (tr)	2002-05-21
HU227966B1 (en)	2012-07-30
PL352483A1 (en)	2003-08-25
DE60001564D1 (de)	2003-04-10
EP1183255A1 (de)	2002-03-06
ATE233762T1 (de)	2003-03-15
DE60001564T2 (de)	2003-12-11
ES2188556T3 (es)	2003-07-01
HUP0201468A2 (en)	2002-08-28
KR20020008218A (ko)	2002-01-29
IL146304A (en)	2006-04-10
PT1183255E (pt)	2003-06-30
BR0011436A (pt)	2002-03-05

Legal Events

Date	Code	Title	Description
2002-06-05	C10	Entry into substantive examination
2002-06-05	SE01	Entry into force of request for substantive examination
2002-06-19	C06	Publication
2002-06-19	PB01	Publication
2005-04-13	C14	Grant of patent or utility model
2005-04-13	GR01	Patent grant
2020-06-02	CF01	Termination of patent right due to non-payment of annual fee
2020-06-02	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20050413 Termination date: 20190608

Publication	Publication Date	Title
CN1196702C (zh)	2005-04-13	二环聚氨基酸金属配合物、它们的制备方法及在医疗图像中的用途
CN1132822C (zh)	2003-12-31	取代的聚氨基羧酸大环化合物的金属螯合物和其在诊断成象中的应用
CN1148360C (zh)	2004-05-05	用于制备用作造影剂的级联聚合配合物的中间产物
CN1083431C (zh)	2002-04-24	新的杂环化合物
CN1028758C (zh)	1995-06-07	吡唑并嘧啶酮类抗心绞痛剂的制备方法
CN1022411C (zh)	1993-10-13	含氮环状配合物的制备方法
CN1110974A (zh)	1995-11-01	聚胺化的配位体及其金属配合物
CN1922138A (zh)	2007-02-28	芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途
CN1126468A (zh)	1996-07-10	氟烷氧基取代的苯甲酰胺类及其作为环状核苷酸磷酸二酯酶抑制剂的应用
CN1620438A (zh)	2005-05-25	用作cbi拮抗剂的5,6－二芳基－吡嗪－2－酰胺衍生物
CN1662509A (zh)	2005-08-31	可用作激酶抑制剂的吡咯并三嗪苯胺化合物
CN1735615A (zh)	2006-02-15	用作激酶抑制剂的吡咯并三嗪化合物的制备方法
CN1131214C (zh)	2003-12-17	作为兴奋性氨基酸拮抗剂的四氢喹啉衍生物
CN1446218A (zh)	2003-10-01	苯并咪唑衍生物,它们的制备方法以及它们的治疗应用
CN1044464A (zh)	1990-08-08	二氮杂双环抗焦虑药
CN1845921A (zh)	2006-10-11	金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1118467C (zh)	2003-08-20	1,3,8－三氮杂螺[4,5]癸－4－酮衍生物
CN1152880A (zh)	1997-06-25	使用含氮大环配拉体的金属络合物的诊断图像分析的方法
CN1139580C (zh)	2004-02-25	取代的苄胺及它们用于治疗抑郁症的用途
CN1064355C (zh)	2001-04-11	大环螯合剂及其螯合物及其在诊断领域的应用
CN1071915A (zh)	1993-05-12	作为兴奋性氨基酸神经传递素拮抗药的合成杂芳基多胺
CN1043990C (zh)	1999-07-07	咪唑啉酮衍生物、其酸的加成盐及老年痴呆症的治疗药物
CN1100767C (zh)	2003-02-05	大环金属配合物羧酸,其用途及制备方法
CN1468113A (zh)	2004-01-14	包含全氟烷基和极性基团的络合物、其制备方法以及在诊断中的应用
CN1069027A (zh)	1993-02-17	具有取代芳酰胺部分的氨基羧化物配合体